Nathália Ferrare
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nathália Ferrare has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- André Ferreira Leite
Universidade de Brasília
4 shared publications - Nilce Santos de Melo
Universidade de Brasília
4 shared publications - Paulo Tadeu de Souza Figueiredo
Dentistry Department, University of Brasília, Brasília, Distrito Federal, Brazil
4 shared publications - Andreia Maria Rocha Moreira
Department of Dentistry, Faculty of Health Sciences, University of Brasília, Campus Universitário Darcy Ribeiro, Asa Norte, Zip Code: 70910-900, Brasília, Brazil
2 shared publications - Carla Ruffeil Moreira Mesquita
Dentistry Department, Faculty of Health Science, Brasilia University, Brasilia, Brazil
2 shared publications - Cristine Miron Stefani
University of Brasilia
2 shared publications
Latest Publications
- 18 March 2021
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 29 (7) , 4171-4173
Correction to: Differences between bisphosphonate-related and denosumab-related osteonecrosis of the jaws: a systematic review
- 18 March 2021
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 29 (7) , 4171-4173
Correction to: Differences between bisphosphonate-related and denosumab-related osteonecrosis of the jaws: a systematic review
- 2 November 2020
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 29 (6) , 2811-2820
Differences between bisphosphonate-related and denosumab-related osteonecrosis of the jaws: a systematic review
Objective Bisphosphonates and denosumab are both antiresorptive medications, each with their own mechanism of action; yet both may result in the same adverse effect: medication-related osteonecrosis of the jaw (ONJ). The present systematic review aims to answer the following question: “Are bisphosphonate-related ONJ and denosumab-related ONJ any different, regarding clinical and imaging aspects?” Methods This review followed the Joanna Briggs Review’s Manual, and the searches were performed on PubMed, Cochrane, Scopus, Web of Science, and Lilacs databases and on the grey literature (ProQuest, Open Grey, and Google Scholar). Results The searches resulted in 7535 articles that were critically assessed. Based on the selection criteria, seven studies were included in the review: five cross-sectional studies and two randomized clinical trials. A total of 7755 patients composed the final population. An increase in bone sequestra, cortical bone lysis, and bone density was observed in bisphosphonate-related ONJ, while larger bone sequestra, more frequent periosteal reactions, and mandibular canal enhancement were noted in denosumab-related ONJ. Conclusion This systematic review demonstrated that the imaging characteristics of bisphosphonate-related and denosumab-related ONJ are not similar. Although clinically similar conditions, they were found to be radiographically distinct. More studies are necessary to further elucidate these differences.
- 2 November 2020
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 29 (6) , 2811-2820
Differences between bisphosphonate-related and denosumab-related osteonecrosis of the jaws: a systematic review
Objective Bisphosphonates and denosumab are both antiresorptive medications, each with their own mechanism of action; yet both may result in the same adverse effect: medication-related osteonecrosis of the jaw (ONJ). The present systematic review aims to answer the following question: “Are bisphosphonate-related ONJ and denosumab-related ONJ any different, regarding clinical and imaging aspects?” Methods This review followed the Joanna Briggs Review’s Manual, and the searches were performed on PubMed, Cochrane, Scopus, Web of Science, and Lilacs databases and on the grey literature (ProQuest, Open Grey, and Google Scholar). Results The searches resulted in 7535 articles that were critically assessed. Based on the selection criteria, seven studies were included in the review: five cross-sectional studies and two randomized clinical trials. A total of 7755 patients composed the final population. An increase in bone sequestra, cortical bone lysis, and bone density was observed in bisphosphonate-related ONJ, while larger bone sequestra, more frequent periosteal reactions, and mandibular canal enhancement were noted in denosumab-related ONJ. Conclusion This systematic review demonstrated that the imaging characteristics of bisphosphonate-related and denosumab-related ONJ are not similar. Although clinically similar conditions, they were found to be radiographically distinct. More studies are necessary to further elucidate these differences.
- 1 September 2018
- Published by Elsevier in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
- Vol. 126 (3) , e150
Early Bony Changes Associated with Bisphosphonate-Related Osteonecrosis of the Jaws in Rats: an in Vivo Study
- 1 September 2018
- Published by Elsevier in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
- Vol. 126 (3) , e150
Early Bony Changes Associated with Bisphosphonate-Related Osteonecrosis of the Jaws in Rats: an in Vivo Study
- 1 October 2017
- Published by Elsevier in Archives of Oral Biology
- Vol. 82, 79-85
Early bony changes associated with bisphosphonate-related osteonecrosis of the jaws in rats: A longitudinal in vivo study
- 1 October 2017
- Published by Elsevier in Archives of Oral Biology
- Vol. 82, 79-85
Early bony changes associated with bisphosphonate-related osteonecrosis of the jaws in rats: A longitudinal in vivo study